Jaguar Health, Inc.
10.8.2021 22:31:50 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
Company plans to file Q2 2021 10-Q on August 13, 2021
SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.
Participation Instructions for Webcast
When: Friday, August 13, 2021 at 8:00 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that an investor webcast will take place August 13, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/659222/Jaguar-Health-Announces-Time-Change-for-Friday-August-13th-Investor-Webcast-to-800-AM-Eastern-Time
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
IROS 2026|PaXini Showcases Full-Stack Tactile Strategy for Physical AI8.10.2026 18:15:00 CEST | Press release
PITTSBURGH, PA / ACCESS Newswire / October 8, 2026 / As global researchers and industry leaders gathered in Pittsburgh for IROS 2026 (Sep. 27-Oct. 1) to tackle the scaling of Physical AI, PaXini AI took center stage, showcasing its full-stack products from chips to humanoid robots and hosting GEEN 2026 · IROS, the Global Embodied Ecosystem Night. The event was not merely an exchange, but an industry gathering focused on the deployment of embodied intelligence. As a leader in tactile sensing, PaXini has built a full-stack closed loop centered on touch: PIE - Perception, Intelligence, Execution. Perception enables robots to understand the real environment more comprehensively and accurately. Intelligence uses data and experience to move robots from being programmed to adapting and generalizing. Execution, through powerful actuators and dexterous end-effectors, allows robots to complete complex tasks. These three layers drive one another and form PaXini's infrastructure capability for the
Loar Holdings Inc. Announces Date and Time for Third Quarter 2026 Earnings and Conference Call7.10.2026 22:05:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / October 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q3 2026 earnings before the market opens on Thursday, November 5, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loa
Surmodics Launches IOL Cartridge Coating Automation Center in Horsham7.10.2026 21:30:00 CEST | Press release
HORSHAM, PA / ACCESS Newswire / October 7, 2026 / Surmodics, a provider of surface technologies and performance coatings for the medical device industry, today announced at the opening of the American Academy of Ophthalmology annual meeting in New Orleans the launch of its IOL Cartridge Coating Automation Center at its Horsham, Pennsylvania site just outside Philadelphia. "The delivery system for an intraocular lens (IOL) combines precision injection-molded parts with a specifically selected lubricious, biofriendly coating," said Chip Hance, CEO of Surmodics. "As IOL manufacturers increasingly seek automated assembly and modern biomaterial formulations, our Automation Center provides automated coating processes designed for efficient production throughout the product lifecycle." The center brings together advanced hydrophilic coating technology, decades of IOL cartridge application expertise, precision coatings processes and automation capabilities in a manufacturing platform developed
Nevada Court Lifts Restriction, Clearing EESystem to Share Recording of November 2024 Meeting7.10.2026 15:00:00 CEST | Press release
LAS VEGAS, NV / ACCESS Newswire / October 7, 2026 / On September 25, 2026, Judge Erika Mendoza of the Eighth Judicial District Court of Nevada, Clark County, entered a written order denying Jason Shurka's motion for a preliminary injunction and granting Michael Bertolacini's motion to dissolve a temporary restraining order that had barred public dissemination of a recording of a November 14, 2024 meeting. The ruling was issued in Case No. A-25-910216-B, Department XXVII, a matter brought by Energy Enhancement System LLC ("EESystem"), Michael Bertolacini and Dr. Sandra Rose Michael against Jason Shurka and other defendants. In its written order, the court stated that its earlier suggestion that Jason Shurka's consent was needed to share the recording was incorrect, and that the restriction was dissolved as of the September 2, 2026 hearing. According to the order, the meeting was recorded on a cellphone by Manny Shurka, Jason Shurka's father, and Jason Shurka produced that recording in t
Steelcase 2025 Impact Report Highlights Progress in Reducing Emissions and Strengthening Communities7.10.2026 15:00:00 CEST | Press release
GRAND RAPIDS, MI / ACCESS Newswire / October 7, 2026 / Steelcase, a global design and thought leader in the world of work, today released its 2025 Impact Report, "Our Work Toward Better Futures." Steelcase recorded reductions in scope 1 and 2 emissions by 33% from its 2019 baseline and activated 324 Better Futures Community partnerships across 38 locations. The report details how Steelcase members, customers and partners are helping communities thrive and moving the organization closer to net zero. "Our commitments to people and the planet help focus the choices we make, the partnerships we build and the value we create," said Megan Blazina, senior vice president, international, digital and strategy at Steelcase, who also leads sustainability and social impact. "The progress in this report reflects how we're turning those commitments into action." As Steelcase looks ahead as a new part of HNI Corporation, the companies' shared focus on the wellbeing of people and the planet provides a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom